Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and pharmacokinetics of HP-6050 microneedle in delirium, psychomotor agitation, and irritability
jRCT2031250405Recruiting
- Sponsor
- Hisamitsu Pharmaceutical Co., Inc.
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of HP-6050 in delirium, psychomotor agitation and irritability, sponsored by Hisamitsu Pharmaceutical Co., Inc. Primary endpoints: Adverse events and Plasma drug concentration. Started Oct 2025; status: recruiting.
02
Drugs
HP-6050
03
Conditions
deliriumpsychomotor agitationirritability
Beyond the preview
Go deeper on jRCT2031250405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250405.